Penarth-headquartered medical diagnostic equipment provider EKF has secured a distribution deal with Asahi Kasei, a Japanese company, to market its product in the US.

Insider Media reports the product is used in measuring glycated albumin, a marker used to determine blood glucose control for people with diabetes. Measuring glycated albumin is also useful for pregnant women and people with dialysis, as well as other conditions.

Under the distribution agreement EKF will undertake marketing, promotion and distribution of the product, which will be manufactured by Asahi Kasei. The product, Lucica GA, will be sold through EKF’s established reagent sales network in the US and sold alongside EKF’s clinical chemistry products which are currently used in over one thousand one hundred hospitals in the US.

Julian Baines, chief executive of EKF, said “This US distribution deal is an exciting and original addition to our diabetes portfolio and will work really well alongside BhB. In addition the agreement will create an additional revenue line in our clinical chemistry portfolio and will utilise our already established US reagent sales channel. We look forward to working with Asahi Kasei to promote a new option of glycemic control to diabetes patients and to healthcare professionals.”